Interpace Biosciences Q2 FY26 swings to GAAP profit of $266,000; revenue falls 1% to $9.1 million

Reuters2026/08/10 20:46

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Interpace Biosciences posted Q2 revenue of USD 9.1 million, down 1% year over year, on a 9% rise in thyroid revenue.
Income from continuing operations turned to profit at USD 0.3 million, including about USD 200,000 of non-recurring professional fees.
Non-GAAP adjusted EBITDA climbed to USD 0.7 million, lifting margin to 8%.
Gross margin expanded to 62% from 54% on a pro forma thyroid-only basis; thyroid test volume rose 6% year over year.
Thyroid lab automation moved into production; pancreatic cancer test development advanced with analytical validation underway and no expected 2026 revenue contribution.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Interpace Biosciences Inc. published the original content used to generate this news brief on August 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Interpace Biosciences Q2 FY26 swings to GAAP profit of $266,000; revenue falls 1% to $9.1 million

You may also like

Crypto prices